Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab has dramatically improved the survival of B-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cerquozzi S, Owen C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ad072ec049fe487aa308dde7eac61360
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ad072ec049fe487aa308dde7eac61360
record_format	dspace
spelling	oai:doaj.org-article:ad072ec049fe487aa308dde7eac613602021-12-02T01:53:16ZClinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia1177-5491https://doaj.org/article/ad072ec049fe487aa308dde7eac613602015-02-01T00:00:00Zhttp://www.dovepress.com/clinical-role-of-obinutuzumab-in-the-treatment-of-naive-patients-with--peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491 Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinutuzumab (GA101) is a novel humanized Type II anti-CD20 monoclonal antibody that has been investigated and compared to rituximab. Here, we provide an overview of obinutuzumab, including its mechanisms of action, preclinical data, and Phase I to III clinical studies. Preclinical data illustrate obinutuzumab's higher potency compared to rituximab through antibody-dependent cellular cytotoxicity and direct cell death. Recently, the CLL11 study presented a significant benefit from obinutuzumab chemoimmunotherapy and supports its use for treatment-naive unfit CLL patients. Herein, we review that obinutuzumab is both a safe and effective alternative to rituximab. Keywords: CLL, GA101, antibody, CD20 Cerquozzi SOwen CDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 13-22 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Cerquozzi S Owen C Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
description	Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinutuzumab (GA101) is a novel humanized Type II anti-CD20 monoclonal antibody that has been investigated and compared to rituximab. Here, we provide an overview of obinutuzumab, including its mechanisms of action, preclinical data, and Phase I to III clinical studies. Preclinical data illustrate obinutuzumab's higher potency compared to rituximab through antibody-dependent cellular cytotoxicity and direct cell death. Recently, the CLL11 study presented a significant benefit from obinutuzumab chemoimmunotherapy and supports its use for treatment-naive unfit CLL patients. Herein, we review that obinutuzumab is both a safe and effective alternative to rituximab. Keywords: CLL, GA101, antibody, CD20
format	article
author	Cerquozzi S Owen C
author_facet	Cerquozzi S Owen C
author_sort	Cerquozzi S
title	Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
title_short	Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
title_full	Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
title_fullStr	Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
title_full_unstemmed	Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
title_sort	clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/ad072ec049fe487aa308dde7eac61360
work_keys_str_mv	AT cerquozzis clinicalroleofobinutuzumabinthetreatmentofnaivepatientswithchroniclymphocyticleukemia AT owenc clinicalroleofobinutuzumabinthetreatmentofnaivepatientswithchroniclymphocyticleukemia
_version_	1718402860720324608

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Ejemplares similares